Literature DB >> 8139608

Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group.

P Martínez-Martín1, A Gil-Nagel, L M Gracia, J B Gómez, J Martínez-Sarriés, F Bermejo.   

Abstract

Our purpose was to verify some basic aspects of validation of the Unified Parkinson's Disease Rating Scale (UPDRS). One hundred and sixty-seven Parkinson's disease (PD) patients were included. Group A (n = 40) was simultaneously assessed by five raters who applied the UPDRS and other PD rating scales (PDRS). A set of timed tests, the Mini-Mental State Examination (MMSE), and the Hamilton Scale for Depression (HSD) were administered by an independent examiner. Group B (n = 127) was individually assessed through the UPDRS and the other PDRSs by one neurologist in four different hospitals. The UPDRS was administered in 16.95 +/- 7.98 min. The internal consistency was high (Cronbach's alpha = 0.96). Nevertheless, the items related to depression, motivation/initiative, and tremor were scarcely consistent. The Interrater reliability was satisfactory (all the items had k > 0.40). There was a high correlation of the UPDRS with the Hoehn and Yahr staging (rs = 0.71; p < 0.001) and some timed tests (finger tapping; arising from chair), but also with the MMSE and HSD (rs = 0.53; rs = 0.64; p < 0.001). The convergent validity with the other PDRS (Intermediate Scale and Schwab and England Scale) was very high (rs = 0.76-0.96; p < 0.001). The factor analysis identified six factors that explained 59.6% of the variance. The dimension "tremor" showed a remarkable independence. The UPDRS is a multidimensional, reliable, and valid scale, with some inconveniences derived from its internal consistency, discriminant validity, and pragmatic application.

Entities:  

Mesh:

Year:  1994        PMID: 8139608     DOI: 10.1002/mds.870090112

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  182 in total

1.  Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease.

Authors:  C S Palmer; J K Schmier; E Snyder; B Scott
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

2.  Disturbed functional brain interactions underlying deficient tactile object discrimination in Parkinson's disease.

Authors:  B Weder; N P Azari; U Knorr; R J Seitz; A Keel; M Nienhusmeier; R P Maguire; K L Leenders; H P Ludin
Journal:  Hum Brain Mapp       Date:  2000-11       Impact factor: 5.038

3.  Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods.

Authors:  Nikie Korver; Piotr J Quee; Heleen B M Boos; Claudia J P Simons; Lieuwe de Haan
Journal:  Int J Methods Psychiatr Res       Date:  2012-03-15       Impact factor: 4.035

4.  Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia.

Authors:  Liana G Apostolova; Mona Beyer; Amity E Green; Kristy S Hwang; Jonathan H Morra; Yi-Yu Chou; Christina Avedissian; Dag Aarsland; Carmen C Janvin; Jan P Larsen; Jeffrey L Cummings; Paul M Thompson
Journal:  Mov Disord       Date:  2010-04-30       Impact factor: 10.338

5.  Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease.

Authors:  Janey Prodoehl; Mathew Spraker; Daniel Corcos; Cynthia Comella; David Vaillancourt
Journal:  Mov Disord       Date:  2010-10-15       Impact factor: 10.338

Review 6.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

7.  Distinct spatiotemporal patterns for disease duration and stage in Parkinson's disease.

Authors:  Simon Badoud; Nicolas Nicastro; Valentina Garibotto; Pierre R Burkhard; Sven Haller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-29       Impact factor: 9.236

8.  A data mining methodology for predicting early stage Parkinson's disease using non-invasive, high-dimensional gait sensor data.

Authors:  Conrad Tucker; Yixiang Han; Harriet Black Nembhard; Mechelle Lewis; Wang-Chien Lee; Nicholas W Sterling; Xuemei Huang
Journal:  IIE Trans Healthc Syst Eng       Date:  2015-11-20

9.  Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing.

Authors:  Andrew M Farrar; Mariana Pereira; Francisco Velasco; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

10.  UPDRS activity of daily living score as a marker of Parkinson's disease progression.

Authors:  Madaline B Harrison; Scott A Wylie; Robert C Frysinger; James T Patrie; Diane S Huss; Lillian J Currie; G Frederick Wooten
Journal:  Mov Disord       Date:  2009-01-30       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.